A5102807072- Trypanosoma species research and implications
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Liver Disease Diagnosis and Treatment
- Parathyroid Disorders and Treatments
- Liver Disease and Transplantation
- Viral Infections and Immunology Research
- Coffee research and impacts
- Cardiovascular Disease and Adiposity
- Hepatocellular Carcinoma Treatment and Prognosis
- Research on Leishmaniasis Studies
- Cardiovascular Effects of Exercise
- Cardiovascular Function and Risk Factors
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Sarcoidosis and Beryllium Toxicity Research
- Youth, Drugs, and Violence
D’Or Institute for Research and Education
2023-2025
Ospedale Santa Maria
2024
San Salvatore Hospital
2023-2024
University of Macerata
2023-2024
Ospedale di Macerata
2024
Presidio Ospedaliero
2023
Istituto Nazionale di Riposo e Cura per Anziani
2023
L'organizzazione Ospedale di Civitanova M
2023
Hospital Universitário Clementino Fraga Filho
2012
Universidade Federal do Rio de Janeiro
2010
INTRODUÇÃO: Morte súbita representa a principal causa de óbito em chagásicos. Eventos fatais pacientes saudáveis, com anormalidades contráteis, foram documentados. O objetivo deste trabalho é determinar associação entre alteração contrátil e arritmias ventriculares complexas chagásicos, classe funcional I, eletrocardiograma normal ou borderline função ventricular preservada. MÉTODOS: Quarenta nove doença Chagas realizaram ecocardiograma, teste ergométrico Holter. Avaliou-se contratilidade...
(1) Background: Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic diseases worldwide. Although cardiovascular and NAFLD risk factors overlap, an independent association between these conditions may exist. Hepatic cardiac fibrosis are important markers mortality, but correlation in patients with has not been well studied. Our main objective was to determine degree myocardial its severity fibrosis. (2) Methods: In this cross-sectional study, were allocated two groups...
Abstract Background A regional network for cardiac amyloidosis (CA) was created in 2019 with the aim of enhancing disease awareness among physicians and favoring appropriate access to innovative diagnostic tools/therapies. The includes all 14 Cardiology Departments outpatient clinics from 5 Local Health Units. Therapies variant (ATTR–v) wild–type (ATTR–wt) CA have recently become available Italy. Selected centres expertise cardiomyopathies were identified prescribe new modifying drugs....
Abstract Background and Methods The management of patients with Cardiac Amyloidosis (CA) Hypertrophic Cardiomyopathy (HCM) is complex requires specific skills. Collaboration between centres remains essential because not all can perform diagnostic techniques (such as endomyocardial biopsy mass spectrometry) or prescribe disease–modifying therapies, Therefore, in 2019 we created a collaborative network for diagnosis treatment CA (TTR AL) HCM (sarcomeric phenocopies) the aim enhancing disease...